Background There is an urgent need for treatments of mild or moderate COVID-19 in an
outpatient setting. Methods A randomized double-blind placebo-controlled clinical trial in 36 …

Background Nitazoxanide is widely available and exerts broad-spectrum antiviral activity in
vitro. However, there is no evidence of its impact on severe acute respiratory syndrome …

Background The absence of specific antivirals to treat COVID-19 leads to the repositioning
of candidates' drugs. Nitazoxanide (NTZ) has a broad antiviral effect. Methods This was a …

The fast spread of COVID-19 has overcrowded Public Health Systems facilities in major
countries due to the large number of seriously ill patients, particularly those requiring …

Background Many treatments are being assessed for repurposing to treat coronavirus
disease 2019 (COVID-19). One drug that has shown promising results in vitro is …

Repurposing approved drugs may rapidly establish effective interventions during a public
health crisis. This has yielded immunomodulatory treatments for severe coronavirus disease …

Background Nitazoxanide exerts antiviral activity in vitro and in vivo and anti-inflammatory
effects, but its impact on patients hospitalized with COVID-19 pneumonia is uncertain …

Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS,
SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 …

TO THE EDITOR: Until specific and effective antiviral therapies against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) become available, the management of …

Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been
declared a global pandemic and urgent treatment and prevention strategies are needed …